The stock of Kamada Ltd (NASDAQ:KMDA) hit a new 52-week high and has $14.61 target or 171.00% above today’s $5.39 share price. The 7 months bullish chart indicates low risk for the $185.74M company. The 1-year high was reported on Oct, 6 by Barchart.com. If the $14.61 price target is reached, the company will be worth $317.62M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 52,159 shares traded hands or 73.12% up from the average. Kamada Ltd (NASDAQ:KMDA) has risen 35.28% since March 3, 2016 and is uptrending. It has outperformed by 26.93% the S&P500.
Analysts await Kamada Ltd (NASDAQ:KMDA) to report earnings on November, 8. They expect $-0.03 EPS, up 76.92% or $0.10 from last year’s $-0.13 per share. After $-0.04 actual EPS reported by Kamada Ltd for the previous quarter, Wall Street now forecasts -25.00% EPS growth.
According to Zacks Investment Research, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel.”
More notable recent Kamada Ltd (NASDAQ:KMDA) news were published by: Seekingalpha.com which released: “Kamada and Shire extend Glassia supply agreement through 2020” on October 06, 2016, also Businesswire.com with their article: “Kamada Announces Third Extension of Strategic Agreement with Baxalta” published on October 16, 2015, Benzinga.com published: “Kamada’s Phase 2 Trial On Inhaled Alpha-1 Antitrypsin Meets Primary Endpoint” on August 30, 2016. More interesting news about Kamada Ltd (NASDAQ:KMDA) were released by: Businesswire.com and their article: “Kamada Announces Publication in Pediatric Diabetes” published on July 06, 2015 as well as Benzinga.com‘s news article titled: “H.C. Wainwright Talks Kamada’s Recent Phase 2 Results” with publication date: September 01, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.